Is Krystal Biotech, Inc. (KRYS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 11.2% / 30% | 1.7% / 30% | 7.24% / 5% | ✗ NOT HALAL |
| DJIM | 0.1% / 33% | 11.2% / 33% | 1.7% / 33% | 7.24% / 5% | ✗ NOT HALAL |
| MSCI | 0.7% / 33% | 62.1% / 33% | 9.6% / 33% | 7.24% / 5% | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 11.2% / 33% | 1.7% / 33% | 7.24% / 5% | ✗ NOT HALAL |
| FTSE | 0.7% / 33% | 62.1% / 33% | 9.6% / 50% | 7.24% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 94.1% | |
| Operating Margin | 41.3% | |
| Net Margin | 52.6% | |
| Return on Equity (ROE) | 18.9% | |
| Return on Assets (ROA) | 8.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $201M |
| Free Cash Flow | $189M |
| Total Debt | $9M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 10.0 |
| Total Assets | $1.3B |
Price & Trading
| Last Close | $251.40 |
| 50-Day MA | $267.45 |
| 200-Day MA | $202.82 |
| Avg Volume | 294K |
| Beta | 0.5 |
|
52-Week Range
$122.80
| |
About Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Krystal Biotech, Inc. (KRYS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Krystal Biotech, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Krystal Biotech, Inc.'s debt ratio?
Krystal Biotech, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are Krystal Biotech, Inc.'s key financial metrics?
Krystal Biotech, Inc. has a market capitalization of $7.2B, trailing P/E ratio of 35.8, and revenue of $389M. The company maintains a gross margin of 94.1% and a net margin of 52.6%. Return on equity stands at 18.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.